MINI LONG - NOVO-NORDISK B | Delayed Börse Stuttgart 11:38:53 26/06/2024 pm IST | ||
| 16.01 EUR | -2.79% |
|
| Current month | +14.60% | ||
| 1 month | +13.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 16.01 | -2.79% |
| 25/24/25 | 16.47 | +6.46% |
| 24/24/24 | 15.47 | -1.02% |
| 21/24/21 | 15.63 | -1.26% |
| 20/24/20 | 15.83 | +3.40% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 11:38 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MD5ZE2 |
| ISIN | DE000MD5ZE20 |
| Date issued | 07/07/2022 |
| Strike | 408.1 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.99 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.7 € |
|---|---|
| Lowest since issue | 0.142 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.86%
- Stock Market
- Certificates
- Certificat
